-
1.发明授权Antibody which specifically binds to endothelial-monocyte activating polypeptide II 失效特异性结合内皮单核细胞活化多肽II的抗体
公开(公告)号：US5641867A
公开(公告)日：1997-06-24
申请号：US129456
申请日：1993-09-29
申请人： David M. Stern , Matthias Clauss , Janet Kao , Mark Kayton , Steven K. Libutti
发明人： David M. Stern , Matthias Clauss , Janet Kao , Mark Kayton , Steven K. Libutti
IPC分类号： G01N33/53 , A61K38/00 , A61K39/395 , A61P35/00 , A61P43/00 , C07H21/04 , C07K14/52 , C07K16/24 , C12N15/09 , C12P21/02 , C12P21/08
摘要： This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).
摘要翻译： 本发明提供纯化的内皮单核细胞活化多肽（EMAP II）。 它进一步提供了获得纯化的内皮单核细胞活化多肽（EMAP II）的方法，一种制备抗体的方法及其检测方法。 本发明还提供了含有与RIGRIVT同源的氨基酸序列的效应细胞活化蛋白及其检测方法。 本发明还提供了通过施用有效剂量的内皮单核细胞活化多肽（EMAP II）来治疗受试者的肿瘤的方法。
-
2.发明授权Endothelial monocyte activating polypeptide II: a mediator which activates host response 失效内皮单核细胞激活多肽II：激活宿主反应的介质公开(公告)号：US06734168B2
公开(公告)日：2004-05-11
申请号：US09851026
申请日：2001-05-07
申请人： David M. Stern , Matthias Clauss , Janet Kao , Mark Kayton , Steven K. Libutti
发明人： David M. Stern , Matthias Clauss , Janet Kao , Mark Kayton , Steven K. Libutti
IPC分类号： A61K3800
摘要： The present invention provides for a purified endothelial monocyte activating polypeptide II, wherein the polypeptide has an apparent molecular weight of about 20,000 Daltons. The present invention also provides for an effector cell activating protein comprising a polypeptide having an amino acid sequence wherein at least four amino acid residues are the same as RIGRTVT and are in the same relative positions. The invention also provides for a DNA which encodes the effector cell activating protein. The invention also provides for methods of inducing inflammation in a subject and methods of treating tumors in a subject. The invention also provides for a pharmaceutical composition which comprises the endothelial monocyte activating polypeptide II and a carrier.
摘要翻译： 本发明提供纯化的内皮单核细胞活化多肽II，其中所述多肽具有约20,000道尔顿的表观分子量。 本发明还提供了一种效应细胞活化蛋白，其包含具有氨基酸序列的多肽，其中至少四个氨基酸残基与RIGRTVT相同并且处于相同的相对位置。 本发明还提供编码效应细胞活化蛋白的DNA。 本发明还提供了在受试者中诱导炎症的方法和治疗受试者肿瘤的方法。 本发明还提供了包含内皮单核细胞活化多肽II和载体的药物组合物。
-
3.发明授权Endothelial monocyte activating polypeptide II: a mediator which activates host response 失效内皮单核细胞激活多肽II：激活宿主反应的介质公开(公告)号：US06228837B1
公开(公告)日：2001-05-08
申请号：US08360821
申请日：1996-10-08
申请人： David M. Stern , Matthias Clauss , Janet Kao , Mark Kayton , Steven K. Libutti
发明人： David M. Stern , Matthias Clauss , Janet Kao , Mark Kayton , Steven K. Libutti
IPC分类号： A61K3800
摘要： This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).
摘要翻译： 本发明提供纯化的内皮单核细胞活化多肽（EMAP II）。 它进一步提供了获得纯化的内皮单核细胞活化多肽（EMAP II）的方法，一种制备抗体的方法及其检测方法。 本发明还提供了含有与RIGRIVT同源的氨基酸序列的效应细胞活化蛋白及其检测方法。 本发明还提供了通过施用有效剂量的内皮单核细胞活化多肽（EMAP II）来治疗受试者的肿瘤的方法。
-
4.发明申请MONOCLONAL ANTIBODY AND ANTIGENS FOR DIAGNOSING AND TREATING LUNG DISEASE AND INJURY 审中-公开用于诊断和治疗肺部疾病和伤害的单克隆抗体和抗原公开(公告)号：US20140221607A1
公开(公告)日：2014-08-07
申请号：US14124439
申请日：2012-06-08
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , A61K2039/505 , C07K16/18 , C07K16/2866 , C07K2317/73 , C07K2317/76
摘要： The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression.
摘要翻译： 本发明提供了通过检测样品中EMAP II的水平来诊断患有肺气肿，由烟草使用引起的肺损伤的COPD的患者的方法。 本文公开了与EMAP II形式结合的大鼠单克隆抗体的高变区。 本公开还包括作为抗体与其靶蛋白的结合的靶标的EMAP II中包含的多肽序列。 该表位作为人源化抗体的基础，其可用于治疗患有显示升高的EMAP II表达水平的病理的患者。
-
公开(公告)号：US08486405B2
公开(公告)日：2013-07-16
申请号：US13309479
申请日：2011-12-01
IPC分类号： A61K39/395 , C07K16/24
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/158 , G01N33/6863 , G01N2800/12 , G01N2800/122 , G01N2800/50
摘要： The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3.
摘要翻译： 本发明提供了通过检测样品中EMAP II的水平来诊断患有肺气肿或COPD的患者的方法。 或者，提供了通过检测样品中EMAP II的水平来确定患者发展为肺气肿或COPD的易感性的方法。 EMAP II的水平可以通过免疫测定技术来确定。 本发明还提供了治疗有效量的EMAP II中和化合物治疗肺气肿或COPD患者的方法。 该化合物可以是抗体，siRNA，反义RNA或CXCR3的拮抗剂。
-
公开(公告)号：US20110142846A1
公开(公告)日：2011-06-16
申请号：US12933278
申请日：2009-03-20
IPC分类号： A61K39/395 , G01N33/68 , A61K31/713 , C07K16/24 , A61P11/00
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/158 , G01N33/6863 , G01N2800/12 , G01N2800/122 , G01N2800/50
摘要： The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3.
摘要翻译： 本发明提供了通过检测样品中EMAP II的水平来诊断患有肺气肿或COPD的患者的方法。 或者，提供了通过检测样品中EMAP II的水平来确定患者发展为肺气肿或COPD的易感性的方法。 EMAP II的水平可以通过免疫测定技术来确定。 本发明还提供了治疗有效量的EMAP II中和化合物治疗肺气肿或COPD患者的方法。 该化合物可以是抗体，siRNA，反义RNA或CXCR3的拮抗剂。
-
公开(公告)号：US20120195906A1
公开(公告)日：2012-08-02
申请号：US13309479
申请日：2011-12-01
IPC分类号： A61K39/395 , A61P11/00 , A61K31/713
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/158 , G01N33/6863 , G01N2800/12 , G01N2800/122 , G01N2800/50
摘要： The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3.
摘要翻译： 本发明提供了通过检测样品中EMAP II的水平来诊断患有肺气肿或COPD的患者的方法。 或者，提供了通过检测样品中EMAP II的水平来确定患者发展为肺气肿或COPD的易感性的方法。 EMAP II的水平可以通过免疫测定技术来确定。 本发明还提供了治疗有效量的EMAP II中和化合物治疗肺气肿或COPD患者的方法。 该化合物可以是抗体，siRNA，反义RNA或CXCR3的拮抗剂。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.03 秒)
